Short answer
Aclaris Therapeutics, Inc. (ACRS) filed an 8-K current report with the SEC on April 28, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Filing contains only standard Regulation FD exhibit-disclaimer language.
Aclaris Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Filing contains only standard Regulation FD exhibit-disclaimer language
- No substantive business, financial, or investor-impacting disclosure in the provided text
Item 8.01 · Other Events
- Press release announced ATI-052 results and an ATI-2138 trial update
- Clinical-program disclosure potentially relevant to Aclaris’s pipeline valuation and development outlook
- Full efficacy, safety, and trial details available in Exhibit 99.2
Item EX-99.1 · Exhibit EX-99.1
- ATI-052 Phase 1 SAD/MAD results support extended dosing, with estimated 45-day half-life and potential up-to-quarterly administration
- Complete or near-complete TSLP and IL-4 inhibition sustained up to five months at 240mg and 480mg MAD doses
- Favorable safety profile across cohorts, with no serious adverse events, discontinuations, Grade 3 drug-related events, or conjunctivitis
- Phase 1b asthma and atopic dermatitis readouts expected 2H 2026, with Phase 2b asthma program targeted for 4Q 2026
- ATI-2138 Phase 2b lichen planus trial planned for 2H 2026, targeting an estimated $1B-$4B peak U.S. revenue opportunity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aclaris Therapeutics, Inc. 8-K filings
Get the next ACRS 8-K as it lands
Follow ACRS for push alerts, or ask the research agent what this filing means.